Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 1;48(10):1794-1802.
doi: 10.2337/dc25-0716.

Continuous Glucose Monitoring Metrics Predict All-Cause Mortality in Diabetes: A Real-world Long-term Study

Affiliations

Continuous Glucose Monitoring Metrics Predict All-Cause Mortality in Diabetes: A Real-world Long-term Study

Tomoki Okuno et al. Diabetes Care. .

Abstract

Objective: Investigate the association between continuous glucose monitoring (CGM)-derived glucose metrics and all-cause mortality in patients with type 1 or type 2 diabetes (T1D or T2D).

Research design and methods: We analyzed data from 2,752 adults (≥21 years old) with diabetes (65% T2D) from the Veterans Affairs Healthcare System who received Dexcom CGM between 2015 and 2020. All participants had ≥10 days of CGM data over landmark (LM) periods (14 days, 3 months, and 6 months) merged with electronic health records. All-cause mortality was assessed over 5 years from CGM initiation. Cox models evaluated associations between mortality and CGM metrics: mean glucose (MG, mg/dL), time in range (TIR, %), time above range (TAR, %), coefficient of variation (CV), and glycemic risk index (GRI, %).

Results: Mean age at CGM initiation was 64 years, and median CGM use was nearly 3 years. There were 407 deaths. In separate multivariable Cox models (adjusting for mortality-related variables), higher MG, TAR, CV, and GRI and lower TIR during the 6-month LM were associated with 5-year mortality (hazard ratios: MG 1.18, TAR 1.20, GRI 1.23, CV 1.18, and TIR 0.83; all P ≤ 0.01) and those associations remained significant after adjusting for LM HbA1c. Results were similar with shorter CGM LM observation windows. The association between CV and mortality was independent of other CGM metrics and appeared strongest in those with lower HbA1c levels.

Conclusions: CGM-derived metrics were associated with all-cause mortality in patients with diabetes and may better capture long-term risk associated with glucose fluctuations and periods of hypo- and hyperglycemia than HbA1c.

PubMed Disclaimer

Conflict of interest statement

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Figures

None
Graphical abstract
Figure 1
Figure 1
Linear or penalized spline risk curves for nonstandardized glycemic exposures over the 6-month LM period in the age-adjusted model. The optimal models based on the corrected Akaike information criteria were nonlinear (two degrees of freedom in the spline term) for LM HbA1c and MG and linear for TIR, TAR, GRI, and CV. The level of LM HbA1c associated with the lowest risk of all-cause mortality was 7.8%, falling between the two reference thresholds (6.2% and 9.0%). The reference values for CGM exposures were as follows: MG 178.5 mg/dL, TIR 56.0%, TAR 42.5%, GRI 49.3%, and CV 33.1%. We defined the reference threshold as the mean predicted risk of all-cause mortality across the range of exposure values in the sample. The dashed line represents a 95% CI.

References

    1. Battelino T, Conget I, Olsen B, et al. ; SWITCH Study Group . The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55:3155–3162 - PMC - PubMed
    1. Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt NM.. Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care 2012;35:32–38 - PMC - PubMed
    1. Beck RW, Riddlesworth T, Ruedy K, et al. ; DIAMOND Study Group . Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 2017;317:371–378 - PubMed
    1. Charleer S, De Block C, Van Huffel L, et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study. Diabetes Care 2020;43:389–397 - PubMed
    1. Gavin JR, Bailey CJ.. Real-world studies support use of continuous glucose monitoring in type 1 and type 2 diabetes independently of treatment regimen. Diabetes Technol Ther 2021;23:S19–S27 - PubMed